Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study aims to determine if one of three low doses of lithium therapy for 6 months can
engage one or more blood-based therapeutic targets implicated in Parkinson's disease (PD)
pathophysiology. Results of this study will help to determine if lithium therapy is
worthwhile to further investigate as a potential disease-modifying therapy in PD, the optimal
dose to study and the optimal PD subgroup most likely to benefit from lithium therapy.